Table 1.
Tissue microarray assay of PGK1 expression in kidney renal clear cell carcinoma (No. HKid-CRC180Sur-01, Outdo Biotech).
| Immunoreactivity | KIRCa (n = 90) | NATb (n = 90) | ||||
|---|---|---|---|---|---|---|
| Percentage | Total | Averagee | Percentage | Total | Average | |
| Weakc | 1.11% (1/90) | 2 | 2 | 32.22% (29/90) | 62 | 2.14 ± 0.69 |
| Moderatec | 2.22% (2/90) | 12 | 6 | 56.67% (51/90) | 256 | 5.02 ± 1.01 |
| Slightly strongc | 42.22% (38/90) | 336 | 8.84 ± 0.37 | 11.11% (10/90) | 84 | 8.40 ± 0.52 |
| Strongc | 54.44% (49/90) | 588 | 12 | 0% (0/0) | 0 | 0 |
| Total***d | 100% (90/90) | 938 | 10.42 ± 1.93 | 100% (90/90) | 402 | 4.47 ± 2.11 |
aKIRC: kidney renal clear cell carcinoma.
bNAT: normal adjacent tissue.
cThe weak, moderate, slightly strong and strong PGK1 levels were scored 1–3, 4–6, 7–9, 10–12, respectively.
dThe immunoreactivity differences between RCC and NAT groups were estimated using Student’s t test, ***P < 0.001.
eExperimental values are represented as means ± SD.